Ketamine Treatment and Blood Pressure: Why Monitoring Is a Core Part of the Intervention

Public discussion of ketamine for depression usually centres on speed of response. Clinically, one of the more important issues is that treatment is not simply prescribed and left alone. The FDA prescribing information for Spravato states that blood pressure should be assessed before administration and reassessed after dosing, because the medication can cause increases in blood pressure that peak at around 40 minutes after administration and may last for around 4 hours. The label also states that if baseline blood pressure is elevated, clinicians should weigh the risks and benefits before proceeding.

This is a useful corrective to simplified descriptions of ketamine as just a fast-acting mood treatment. The monitoring requirements are built into the treatment pathway. The FDA label also requires observation for at least 2 hours after each treatment session because of risks including sedation, dissociation, and respiratory depression, and the product is restricted through a REMS programme. That means ketamine-based treatment is, by design, a supervised medical intervention rather than a routine outpatient prescription model.

The blood pressure issue also helps explain why suitability matters. The label advises close monitoring when Spravato is used with psychostimulants or monoamine oxidase inhibitors, and notes that people with certain vascular or hypertensive risks may need more intensive assessment. In practice, this means that a treatment pathway has to account not only for depressive symptoms, but for medical history, current medications, and the person’s ability to attend monitored sessions.

So one of the clearest ways to describe ketamine treatment accurately is to focus on monitoring rather than novelty. The clinical picture is not just about whether the treatment can work. It is about whether it can be delivered safely, consistently, and under the level of oversight that the medication requires.